NCT06938711 2025-04-22A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerContext Therapeutics Inc.Phase 1/2 Withdrawn